H. R. 6344—13
‘‘(i) Comprehensive, research-based, long-range, 
quantifiable goals for reducing illicit drug use and 
the consequences of illicit drug use in the United 
States. 
‘‘(ii) Annual quantifiable and measurable objectives 
and specific targets to accomplish long-term quantifi-
able goals that the Director determines may be 
achieved during each year beginning on the date on 
which the National Drug Control Strategy is sub-
mitted. 
‘‘(iii) A 5-year projection for program and budget 
priorities. 
‘‘(iv) A review of international, State, local, and 
private sector drug control activities to ensure that 
the United States pursues coordinated and effective 
drug control at all levels of government. 
‘‘(v) An assessment of current illicit drug use 
(including inhalants and steroids) and availability, 
impact of illicit drug use, and treatment availability, 
which assessment shall include—
‘‘(I) estimates of drug prevalence and fre-
quency of use as measured by national, State, 
and local surveys of illicit drug use and by other 
special studies of nondependent and dependent 
illicit drug use; 
‘‘(II) illicit drug use in the workplace and the 
productivity lost by such use; and 
‘‘(III) illicit drug use by arrestees, proba-
tioners, and parolees. 
‘‘(vi) An assessment of the reduction of illicit drug 
availability, as measured by—
‘‘(I) the quantities of cocaine, heroin, mari-
juana, methamphetamine, ecstasy, and other drugs 
available for consumption in the United States; 
‘‘(II) the amount of marijuana, cocaine, heroin, 
methamphetamine, ecstasy, and precursor chemi-
cals and other drugs entering the United States; 
‘‘(III) the number of illicit drug manufacturing 
laboratories seized and destroyed and the number 
of hectares of marijuana, poppy, and coca cul-
tivated and destroyed domestically and in other 
countries; 
‘‘(IV) the number of metric tons of marijuana, 
heroin, cocaine, and methamphetamine seized and 
other drugs; and 
‘‘(V) changes in the price and purity of heroin, 
methamphetamine, and cocaine, changes in the 
price 
of 
ecstasy, 
and 
changes 
in 
tetrahydrocannabinol level of marijuana and other 
drugs. 
‘‘(vii) An assessment of the reduction of the con-
sequences of illicit drug use and availability, which 
shall include—
‘‘(I) the burden illicit drug users placed on 
hospital emergency departments in the United 
States, such as the quantity of illicit drug-related 
services provided;
H. R. 6344—14
‘‘(II) the annual national health care cost of 
illicit drug use; and 
‘‘(III) the extent of illicit drug-related crime 
and criminal activity. 
‘‘(viii) A determination of the status of drug treat-
ment in the United States, by assessing—
‘‘(I) public and private treatment utilization; 
and 
‘‘(II) the number of illicit drug users the 
Director estimates meet diagnostic criteria for 
treatment. 
‘‘(ix) A review of the research agenda of the 
Counterdrug Technology Assessment Center to reduce 
the availability and abuse of drugs. 
‘‘(x) A summary of the efforts made to coordinate 
with private sector entities to conduct private research 
and development of medications to treat addiction by—
‘‘(I) screening chemicals for potential thera-
peutic value; 
‘‘(II) developing promising compounds; 
‘‘(III) conducting clinical trials; 
‘‘(IV) seeking Food and Drug Administration 
approval for drugs to treat addiction; 
‘‘(V) marketing the drug for the treatment of 
addiction; 
‘‘(VI) urging physicians to use the drug in 
the treatment of addiction; and 
‘‘(VII) encouraging insurance companies to 
reimburse the cost of the drug for the treatment 
of addiction. 
‘‘(xi) An assessment of Federal effectiveness in 
achieving the National Drug Control Strategy for the 
previous year, including a specific evaluation of 
whether the objectives and targets for reducing illicit 
drug use for the previous year were met and reasons 
for the success or failure of the previous year’s 
Strategy. 
‘‘(xii) A general review of the status of, and trends 
in, demand reduction activities by private sector enti-
ties and community-based organizations, including 
faith-based organizations, to determine their effective-
ness and the extent of cooperation, coordination, and 
mutual support between such entities and organiza-
tions and Federal, State, local, and tribal government 
agencies. 
‘‘(xiii) Such additional statistical data and informa-
tion as the Director considers appropriate to dem-
onstrate and assess trends relating to illicit drug use, 
the effects and consequences of illicit drug use 
(including the effects on children of substance abusers), 
supply reduction, demand reduction, drug-related law 
enforcement, and the implementation of the National 
Drug Control Strategy. 
‘‘(xiv) A supplement reviewing the activities of each 
individual National Drug Control Program agency 
during the previous year with respect to the National 
Drug Control Strategy and the Director’s assessment
H. R. 6344—15
of the progress of each National Drug Control Program 
agency in meeting its responsibilities under the 
National Drug Control Strategy. 
‘‘(B) CLASSIFIED
INFORMATION.—Any contents of the 
National Drug Control Strategy that involve information 
properly classified under criteria established by an Execu-
tive order shall be presented to Congress separately from 
the rest of the National Drug Control Strategy. 
‘‘(C) SELECTION
OF
DATA
AND
INFORMATION.—In 
selecting data and information for inclusion under subpara-
graph (A), the Director shall ensure—
‘‘(i) the inclusion of data and information that will 
permit analysis of current trends against previously 
compiled data and information where the Director 
believes such analysis enhances long-term assessment 
of the National Drug Control Strategy; and 
‘‘(ii) the inclusion of data and information to permit 
a standardized and uniform assessment of the effective-
ness of drug treatment programs in the United States. 
‘‘(3) PROCESS
FOR
DEVELOPMENT
AND
SUBMISSION.—In 
developing and effectively implementing the National Drug 
Control Strategy, the Director—
‘‘(A) shall consult with—
‘‘(i) the heads of the National Drug Control Pro-
gram agencies; 
‘‘(ii) Congress; 
‘‘(iii) State, local, and tribal officials; 
‘‘(iv) private citizens and organizations, including 
community and faith-based organizations with experi-
ence and expertise in demand reduction; 
‘‘(v) private citizens and organizations with experi-
ence and expertise in supply reduction; and 
‘‘(vi) appropriate representatives of foreign govern-
ments; 
‘‘(B) in satisfying the requirements of subparagraph 
(A), shall ensure, to the maximum extent possible, that 
State, local, and tribal officials and relevant private 
organizations commit to support and take steps to achieve 
the goals and objectives of the National Drug Control 
Strategy; 
‘‘(C) with the concurrence of the Attorney General, 
may require the El Paso Intelligence Center to undertake 
specific tasks or projects to support or implement the 
National Drug Control Strategy; and 
‘‘(D) with the concurrence of the Director of National 
Intelligence and the Attorney General, may request that 
the National Drug Intelligence Center undertake specific 
tasks or projects to support or implement the National 
Drug Control Strategy. 
‘‘(b) SUBMISSION OF REVISED STRATEGY.—The President may 
submit to Congress a revised National Drug Control Strategy that 
meets the requirements of this section—
‘‘(1) at any time, upon a determination of the President, 
in consultation with the Director, that the National Drug Con-
trol Strategy in effect is not sufficiently effective; or 
‘‘(2) if a new President or Director takes office.’’.
H. R. 6344—16
SEC. 202. PERFORMANCE MEASUREMENTS. 
Section 706 is amended by adding at the end the following: 
‘‘(c) PERFORMANCE MEASUREMENT SYSTEM.—Not later than Feb-
ruary 1 of each year, the Director shall submit to Congress as 
part of the National Drug Control Strategy, a description of a 
national drug control performance measurement system, that—
‘‘(1) develops 2-year and 5-year performance measures and 
targets for each National Drug Control Strategy goal and objec-
tive established for reducing drug use, availability, and the 
consequences of drug use; 
‘‘(2) describes the sources of information and data that 
will be used for each performance measure incorporated into 
the performance measurement system; 
‘‘(3) identifies major programs and activities of the National 
Drug Control Program agencies that support the goals and 
annual objectives of the National Drug Control Strategy; 
‘‘(4) evaluates the contribution of demand reduction and 
supply reduction activities as defined in section 702 imple-
mented by each National Drug Control Program agency in 
support of the National Drug Control Strategy; 
‘‘(5) monitors consistency between the drug-related goals 
and objectives of the National Drug Control Program agencies 
and ensures that each agency’s goals and budgets support 
and are fully consistent with the National Drug Control 
Strategy; and 
‘‘(6) coordinates the development and implementation of 
national drug control data collection and reporting systems 
to support policy formulation and performance measurement, 
including an assessment of—
‘‘(A) the quality of current drug use measurement 
instruments and techniques to measure supply reduction 
and demand reduction activities; 
‘‘(B) the adequacy of the coverage of existing national 
drug use measurement instruments and techniques to 
measure the illicit drug user population, and groups that 
are at risk for illicit drug use; 
‘‘(C) the adequacy of the coverage of existing national 
treatment outcome monitoring systems to measure the 
effectiveness of drug abuse treatment in reducing illicit 
drug use and criminal behavior during and after the 
completion of substance abuse treatment; and 
‘‘(D) the actions the Director shall take to correct any 
deficiencies and limitations identified pursuant to subpara-
graphs (A) and (B) of this subsection. 
‘‘(d) MODIFICATIONS.—A description of any modifications made 
during the preceding year to the national drug performance 
measurement system described in subsection (c) shall be included 
in each report submitted under subsection (b).’’. 
SEC. 203. ANNUAL REPORT REQUIREMENT. 
(a) IN GENERAL.—On or before February 1 of each year, the 
Director shall submit a report to Congress that describes—
(1) the strategy of the national media campaign and 
whether specific objectives of the campaign were accomplished; 
(2) steps taken to ensure that the national media campaign 
operates in an effective and efficient manner consistent with 
the overall strategy and focus of the campaign;
H. R. 6344—17
(3) plans to purchase advertising time and space; 
(4) policies and practices implemented to ensure that Fed-
eral funds are used responsibly to purchase advertising time 
and space and eliminate the potential for waste, fraud, and 
abuse; 
(5) all contracts entered into with a corporation, partner-
ship, or individual working on behalf of the national media 
campaign; 
(6) specific policies and steps implemented to ensure compli-
ance with title IV of this Act; 
(7) steps taken to ensure that the national media campaign 
will secure, to the maximum extent possible, no cost matches 
of advertising time and space or in-kind contributions that 
are directly related to the campaign in accordance with title 
IV of this Act; and 
(8) a review and evaluation of the effectiveness of the 
national media campaign strategy for the past year. 
(b) AUDIT.—The Government Accountability Office shall, at a 
frequency of not less than once per year—
(1) conduct and supervise an audit and investigation 
relating to the programs and operations of the—
(A) Office; or 
(B) certain programs within the Office, including—
(i) the High Intensity Drug Trafficking Areas Pro-
gram; 
(ii) 
the 
Counterdrug 
Technology 
Assessment 
Center; or 
(iii) the National Youth Anti-drug Media Cam-
paign; and 
(2) provide the Director and the appropriate congressional 
committees with a report containing an evaluation of and rec-
ommendations on the—
(A) policies and activities of the programs and oper-
ations subject to the audit and investigation; 
(B) economy, efficiency, and effectiveness in the 
administration of the reviewed programs and operations; 
and 
(C) policy or management changes needed to prevent 
and detect fraud and abuse in such programs and oper-
ations. 
TITLE III—HIGH INTENSITY DRUG 
TRAFFICKING AREAS 
SEC. 301. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM. 
Section 707 is amended to read as follows: 
‘‘SEC. 707. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM. 
‘‘(a) ESTABLISHMENT.—
‘‘(1) IN GENERAL.—There is established in the Office a pro-
gram to be known as the High Intensity Drug Trafficking 
Areas Program (in this section referred to as the ‘Program’). 
‘‘(2) PURPOSE.—The purpose of the Program is to reduce 
drug trafficking and drug production in the United States by—